JP2016512564A - Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 - Google Patents

Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 Download PDF

Info

Publication number
JP2016512564A
JP2016512564A JP2016502000A JP2016502000A JP2016512564A JP 2016512564 A JP2016512564 A JP 2016512564A JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016512564 A JP2016512564 A JP 2016512564A
Authority
JP
Japan
Prior art keywords
receptor agonist
trpv2
trpv2 receptor
diastolic
probenecid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512564A5 (enExample
Inventor
ジャック・ルビンスタイン
キース・ダブリュー・ジョーンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of JP2016512564A publication Critical patent/JP2016512564A/ja
Publication of JP2016512564A5 publication Critical patent/JP2016512564A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016502000A 2013-03-13 2014-03-13 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 Pending JP2016512564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778826P 2013-03-13 2013-03-13
US61/778,826 2013-03-13
PCT/US2014/025930 WO2014160153A1 (en) 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020203311A Division JP2021042248A (ja) 2013-03-13 2020-12-08 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療

Publications (2)

Publication Number Publication Date
JP2016512564A true JP2016512564A (ja) 2016-04-28
JP2016512564A5 JP2016512564A5 (enExample) 2017-06-01

Family

ID=50680137

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502000A Pending JP2016512564A (ja) 2013-03-13 2014-03-13 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP2020203311A Pending JP2021042248A (ja) 2013-03-13 2020-12-08 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP2023196822A Pending JP2024009140A (ja) 2013-03-13 2023-11-20 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020203311A Pending JP2021042248A (ja) 2013-03-13 2020-12-08 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP2023196822A Pending JP2024009140A (ja) 2013-03-13 2023-11-20 Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療

Country Status (7)

Country Link
US (1) US10583103B2 (enExample)
EP (1) EP2968238A1 (enExample)
JP (3) JP2016512564A (enExample)
AU (1) AU2014244053B2 (enExample)
CA (1) CA2904671C (enExample)
MX (1) MX376077B (enExample)
WO (1) WO2014160153A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021246779A1 (ko) * 2020-06-03 2021-12-09 주식회사 삼오파마켐 프로베네시드 및 아르기닌을 포함하는 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법
JP2022553635A (ja) * 2019-10-25 2022-12-26 カーディオル セラピューティクス インコーポレイテッド 心臓病態の治療に使用するためのカンナビジオール組成物
JP2023516284A (ja) * 2020-02-19 2023-04-19 マーチャント，シュリーマ カンナビジオールの組成物および治療的使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
JP6433896B2 (ja) 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
EP3200808B1 (en) 2014-10-03 2024-07-31 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
US11351200B2 (en) 2016-06-03 2022-06-07 Cedars-Sinai Medical Center CDC-derived exosomes for treatment of ventricular tachyarrythmias
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
EP3612191A4 (en) 2017-04-19 2020-12-30 Cedars-Sinai Medical Center METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY
AU2018384096B2 (en) * 2017-12-12 2021-04-15 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN113861633B (zh) * 2021-10-14 2022-12-20 武汉工程大学 一种p-n-b阻燃pbs塑料及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535410A (ja) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド ピロロキノリンキノンおよびその使用
US20130046021A1 (en) * 2011-08-12 2013-02-21 University Of Cincinnati Methods of treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure with probenecid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524917A (en) 1969-02-10 1970-08-18 Merck & Co Inc Tablets of magnesium probenecid tetrahydrate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH01211582A (ja) 1988-02-16 1989-08-24 Tanabe Seiyaku Co Ltd ベンゾジオキソール誘導体
CA2115442C (en) 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US20030212123A1 (en) 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
ATE422357T1 (de) 2000-06-28 2009-02-15 Merck & Co Inc Verwendung von allopurinol zur behandlung von bluthochdruck
AU2001227030A1 (en) 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20080051428A1 (en) 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
AU2003289440A1 (en) 2002-12-25 2004-07-22 Kissei Pharmaceutical Co., Ltd. Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof
WO2005026728A1 (ja) 2003-09-11 2005-03-24 Takeda Pharmaceutical Company Limited スクリーニング方法
DE10352511A1 (de) 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen
CA2545944A1 (en) 2003-11-13 2005-06-02 Board Of Regents, The University Of Texas System Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
CA2555399A1 (en) 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
NZ549628A (en) 2004-03-04 2010-06-25 Kissei Pharmaceutical Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
CA2560005A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
JP2009149534A (ja) 2007-12-18 2009-07-09 Japan Health Science Foundation Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法
KR100951656B1 (ko) 2008-02-25 2010-04-07 고려대학교 산학협력단 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제
ES2613804T3 (es) 2008-07-17 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibidores de MRP4 y agentes que estimulan la actividad de MRP4 para el tratamiento de trastornos cardíacos
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US9216171B2 (en) 2009-05-07 2015-12-22 University Of Cincinnati Methods of preventing ischemic injury using peripheral nociceptive stimulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009535410A (ja) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド ピロロキノリンキノンおよびその使用
US20130046021A1 (en) * 2011-08-12 2013-02-21 University Of Cincinnati Methods of treating cardiomyopathy, systolic cardiac dysfunction and the symptoms of congestive heart failure with probenecid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＡＮＤ ＣＥＬＬＵＬＡＲ ＣＡＲＤＩＯＬＯＧＹ, vol. 53, no. 1, JPN5015008999, 2012, pages 134 - 144, ISSN: 0004020921 *
理学療法学, vol. 39, no. 4, JPN6018041472, 2012, pages 235 - 239, ISSN: 0003904637 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022553635A (ja) * 2019-10-25 2022-12-26 カーディオル セラピューティクス インコーポレイテッド 心臓病態の治療に使用するためのカンナビジオール組成物
JP2023516284A (ja) * 2020-02-19 2023-04-19 マーチャント，シュリーマ カンナビジオールの組成物および治療的使用
WO2021246779A1 (ko) * 2020-06-03 2021-12-09 주식회사 삼오파마켐 프로베네시드 및 아르기닌을 포함하는 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법

Also Published As

Publication number Publication date
CA2904671A1 (en) 2014-10-02
AU2014244053A1 (en) 2015-09-24
AU2014244053B2 (en) 2018-08-30
US20160008305A1 (en) 2016-01-14
JP2024009140A (ja) 2024-01-19
MX376077B (es) 2025-03-07
US10583103B2 (en) 2020-03-10
EP2968238A1 (en) 2016-01-20
CA2904671C (en) 2022-08-30
WO2014160153A1 (en) 2014-10-02
MX2015012547A (es) 2016-02-10
JP2021042248A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
JP2021042248A (ja) Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療
JP7508496B2 (ja) 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
JP2001515864A (ja) 非天然ｆｐ選択的作用薬を使用した骨体積増加方法
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
US11617754B2 (en) Methods of treating heart failure with preserved ejection fraction
Patel et al. Congestive heart failure model representing aortic banding induced hypertrophy: a study to analyse extent of pressure overload and alteration in myocardial structure and function
PT2694074T (pt) Uso de antagonistas de recetor de adenosina a2b para tratar insuficiência cardíaca e arritmia em pacientes pós-enfarte do miocárdio
Xu et al. Ghrelin ameliorates hypoxia-induced pulmonary hypertension via phospho-GSK3 b/b-catenin signaling in neonatal rats
Zhang et al. Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: insights into cellular mechanisms
US20250177353A1 (en) Methods of treating mitochondria-related disorders
US9943518B2 (en) Inhibitors of phosphodiesterase type 5A for reducing skeletal muscle fatigue, edema, and damage in a patient having muscle fatigue due to increased age or exercise
CN109806263A (zh) 一种药物组合物及其制备方法和用途
Nawata et al. Dantrolene improves left ventricular diastolic property in mineralcorticoid-salt-induced hypertensive rats
CN117257803A (zh) 鲁拉西酮在制备治疗或预防缺血/再灌注损伤的药物和细胞保护药物中的应用
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
US20160067246A1 (en) Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
Xu et al. Ang II enhances atrial fibroblast autophagy and promotes atrial remodeling through the AT1-ERK-mTOR signaling pathway
CN110604735B (zh) 一种治疗肝纤维化、硬皮病的化合物及其应用
Torun Approach to cases with resistant hypertension.
Hinkle et al. Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals
TW200900071A (en) Methods of treating heart failure and renal dysfunction in individuals with an adenosine A1 receptor antagonist
Riesen Studies on Myocardial Funny Channels and the Funny Current Inhibitor Ivabradine in Healthy Cats and Cats with Hypertrophic Cardiomyopathy
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
BR102014015781A2 (pt) composição farmacêutica compreendendo lipossomas multilamelares como sistema entregador de piridostigmina

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181029

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190228

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190308

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20190311

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20190419

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20190507

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20191105

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20200608

C28A Non-patent document cited

Free format text: JAPANESE INTERMEDIATE CODE: C2838

Effective date: 20200608

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200908

C141 Inquiry by the administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C141

Effective date: 20210315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210604

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210812

C54 Written response to inquiry

Free format text: JAPANESE INTERMEDIATE CODE: C54

Effective date: 20210915

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211213

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220124

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220124